AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s recent clinical study, titled ‘A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours,’ aims to evaluate the safety, tolerability, and pharmacokinetics of the drug combination in patients with advanced solid tumors. This study is significant as it explores a novel therapeutic approach for treating refractory solid tumors.
The study tests the combination of AZD1775 (Adavosertib), an oral drug, and MEDI4736 (Durvalumab), administered intravenously. The purpose is to assess their combined effect on tumor reduction and patient safety.
This Phase I study is non-randomized with a parallel intervention model, focusing on treatment as its primary purpose. It involves multiple dosing schedules to determine the maximum tolerated dose and gather preliminary efficacy data.
The study began on December 28, 2015, with its latest update submitted on August 12, 2025. These dates are crucial as they mark the study’s progression and recent developments.
The update may influence AstraZeneca’s stock performance positively, as successful outcomes could enhance its competitive position in oncology. Investors might view this as a potential growth opportunity, especially in the context of an evolving cancer treatment landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money